Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL.

Nature. 2011 Mar 24;471(7339):523-6. doi: 10.1038/nature09870.

PMID:
21430781
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.

Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.

PMID:
21430269
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.

Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA.

PLoS One. 2010 Nov 29;5(11):e14124. doi: 10.1371/journal.pone.0014124.

PMID:
21124782
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

PMID:
20610543
[PubMed - indexed for MEDLINE]
Free Article
5.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

PMID:
20571069
[PubMed - indexed for MEDLINE]
Free Article
6.

Inferring dynamic gene networks under varying conditions for transcriptomic network comparison.

Shimamura T, Imoto S, Yamaguchi R, Nagasaki M, Miyano S.

Bioinformatics. 2010 Apr 15;26(8):1064-72. doi: 10.1093/bioinformatics/btq080. Epub 2010 Mar 1.

PMID:
20197286
[PubMed - indexed for MEDLINE]
Free Article
7.

Expression and localization of FOXO1 in non-small cell lung cancer.

Maekawa T, Maniwa Y, Doi T, Nishio W, Yoshimura M, Ohbayashi C, Hayashi Y, Okita Y.

Oncol Rep. 2009 Jul;22(1):57-64.

PMID:
19513505
[PubMed - indexed for MEDLINE]
8.

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.

Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ.

Clin Cancer Res. 2009 May 1;15(9):3023-8. doi: 10.1158/1078-0432.CCR-08-2739. Epub 2009 Apr 14.

PMID:
19366827
[PubMed - indexed for MEDLINE]
Free Article
9.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK.

Cancer Res. 2009 Apr 15;69(8):3256-61. doi: 10.1158/0008-5472.CAN-08-4055. Epub 2009 Apr 7.

PMID:
19351834
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.

PMID:
19328586
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
[PubMed - indexed for MEDLINE]
12.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

PMID:
18997818
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL.

Gastroenterology. 2008 May;134(5):1521-31. doi: 10.1053/j.gastro.2008.02.015. Epub 2008 Feb 13. Erratum in: Gastroenterology. 2008 Jul;135(1):326.

PMID:
18471523
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors.

Terragni J, Graham JR, Adams KW, Schaffer ME, Tullai JW, Cooper GM.

BMC Cell Biol. 2008 Jan 28;9:6. doi: 10.1186/1471-2121-9-6.

PMID:
18226221
[PubMed - indexed for MEDLINE]
Free PMC Article
15.
16.

Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC.

Cell. 2007 Jun 15;129(6):1065-79.

PMID:
17574021
[PubMed - indexed for MEDLINE]
Free Article
17.

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA.

Int J Cancer. 2007 Sep 15;121(6):1390-5.

PMID:
17514651
[PubMed - indexed for MEDLINE]
18.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

PMID:
17463250
[PubMed - indexed for MEDLINE]
Free Article
19.

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2006 Sep;1(7):629-34.

PMID:
17409929
[PubMed - indexed for MEDLINE]
20.

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.

Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E.

Clin Cancer Res. 2007 Mar 1;13(5):1576-83.

PMID:
17332304
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk